Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12?

Similar documents
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Is Cangrelor hype or hope in STEMI primary PCI?

DECLARATION OF CONFLICT OF INTEREST

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Quoi de neuf en cardio-gériatrie? Pr Olivier Hanon Hôpital Broca, Paris

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department

ACCP Cardiology PRN Journal Club

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

On admission Acute extensive anterior STEMI

P2Y 12 blockade. To load or not to load before the cath lab?

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Why and How Should We Switch Clopidogrel to Prasugrel?

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

QUT Digital Repository:

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Thrombosis Research active studies

Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI

Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI

Antiplatelet therapy is the mainstay of pharmacological

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

KCS Congress: Impact through collaboration

Belinda Green, Cardiologist, SDHB, 2016

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Quando (e come) inziare; se (e quando) cambiare. Maddalena Lettino Humanitas Research Hospital, Rozzano Milano, Italy

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

When and how to combine antiplatelet agents and anticoagulant?

Myocardial Infarction In Dr.Yahya Kiwan

Switching antiplatelet regimens: alternatives to clopidogrel in STEMI patients

Timing of Surgery After Percutaneous Coronary Intervention

Nuevos antiagregantes plaquetarios

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Otamixaban for non-st-segment elevation acute coronary syndrome

Dual Antiplatelet Therapy: Time for a Paradigm Shift?

Speaker s name: Thomas Cuisset, MD, PhD

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Selective use of platelet glycoprotein IIb/IIIa inhibition

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Pharmaco-Invasive Approach for STEMI

ACCP Cardiology PRN Journal Club. 24 May 2018

Prise en charge du SCA ST + en urgence. 9803mo01, 1

Πποβλημαηιζμοί με ηην ανηιαιμοπεηαλιακή αγωγή ζηο οξύ έμθπαγμα ηος μςοκαπδίος με ανάζπαζη ηος διαζηήμαηορ ST.

The following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Optimal lenght of DAPT in different clinical scenarios

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

The Korean Society of Cardiology COI Disclosure

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

New antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Novel Anticoagulation Therapy in Acute Coronary Syndrome

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο

No conflict of interest to declare

Dual Antiplatelet Therapy Made Practical

Antiplatelet Therapy and Cardiac Surgery: A Challenge? The use of aspirin and clopidogrel in cardiac surgery

Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές

Case Challenges in ACS The Very Elderly in the Cath Lab

Acute Coronary syndrome

TRANSPARENCY COMMITTEE OPINION. 2 April 2008

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

The Great debate: thrombocardiology post-compass

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Quinn Capers, IV, MD

INDIVIDUALIZED MEDICINE

Updated and Guideline Based Treatment of Patients with STEMI

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?

FastTest. You ve read the book now test yourself

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ

Upcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?

INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Do We Need Platelet Function Assays?

ISCHEMIC HEART DISEASE

Transcription:

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? La Baule Le 17 Mai 2014 Philippe Castellant CHU de Brest, Département de Cardiologie UBO, EA 4324 ORPHY

Questions soulevées SCA ST+/ST-? Quel inhibiteur des P2Y12? Si dose de charge: Pourquoi en amont de la salle de KT?

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST+

Aspirine Inhibiteur des P2Y12

Composition of Coronary Thrombus in Acute Myocardial Infarction Johanne Silvain et al. Journal of the American College of Cardiology Vol. 57, No. 12, 2011

Addition of clopidogrel to Aspirin and Fibrinolytic Therapy for myocardial Infarction with ST-segment Elevation CLARITY-TIMI 28 MS Sabatine et al. NEJM 2005, vol 352 No.12

Cumulative incidence of EP of death from cardiovascular causes, recurrent MI, recurrent ischémia leading to the need for urgent revascularization.

Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics The PCI-CLARITY Study MS Sabatine et al. JAMA, September 14, 2005 Vol 294, No. 10

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. ZM Chen et al. Lancet. 2005 Nov 5;366(9497):1607-21. Exclusion patients ayant déjàbénéficiéd une ATC ou àhaut risque hémorragique Comparaison : 75 mg clopidogrel+ 160 mg aspirine vs aspirine seule Thrombolyse non nécessaire pour être inclus ( étude CLARITY) Critère primaire : l ensemble des évènements CV majeurs: (décès, récidive d IDM, AVC) survenant avant la sortie de l hôpital (durée moyenne de suivi : 16 jours).

Lancet. 2005 Nov 5;366(9497):1607-21.

Circulation 2010:122:2131-2141

p=0.07 p=0.07 p=0.03 P=0.02

Therapeutic approaches in arterial thrombosis R. PHILLIPS et al. Journal of Thrombosis and Haemostasis, 2005: 1577 1589

P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: Fighting against the activated platelets Dimitrios Alexopoulos et al. International Journal of Cardiology 163 (2013) 249 255

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505 16.

Effects of P2Y12 Receptor Inhibition in Patients With ST-Segment Elevation Myocardial Infarction Dimitrios Alexopoulos, et al. Am J Cardiol 2014, March 20, sous presse

Journal of the American College of Cardiology Vol. 56, No. 19, 2010 New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention A Meta-Analysis Anne Bellemain-Appaix, et al. Sous groupe des STEMI

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST+ = DAP

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST+ = DAP en amont de la salle de KT?

Patients undergoing primary PCI should receive a combination of DAPT with aspirin and an adenosine diphosphate (ADP) receptor blocker, as early as possible before angiography No trials to date have evaluated the commencement of DAPT prior to hospital admission, rather than in hospital, nor its use before, rather than during, angiography in the setting of STEMI, but this is common practice in Europe and is consistent with the pharmacokinetic data for oral antithrombotic agents, suggesting that the earliest administration would be preferable to achieve early efficacy.

Composition of Coronary Thrombus in Acute Myocardial Infarction Johanne Silvain et al. Journal of the American College of Cardiology Vol. 57, No. 12, 2011

Thrombus «frais» moins de 3h cristaux de cholestérol plaquettes

Thrombus de plus de 3 heures Riche en eyrthrocytes (b), globules blancs (a), fibrine (c) et quelques plaquettes agréguées (d)

Circulation cardiovascular intervention 2012;5:797-804

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST+ = DAP en amont de la salle de KT pour l instant

Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronaryartery (ATLANTIC) study Gilles Montalescot, et al. Am Heart J 2013;165:515-22

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST-

Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting Thomas Cuisset et al. J Am Coll Cardiol. 2006; 48(7):1339-1345.

J Am Coll Cardiol. 2006; 48(7):1339-1345.

Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, And Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention A Systematic Review and Meta-analysis Anne Bellemain-Appaix, et al JAMA. 2012;308(23):2507-2517

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention Yiding Li et al. J Thromb Thrombolysis (2012) 34:499 505

Journal of the American College of Cardiology Vol. 56, No. 19, 2010 New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention A Meta-Analysis Anne Bellemain-Appaix, et al.

Journal of the American College of Cardiology Vol. 56, No. 19, 2010

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST- = plutôt nouveaux inhibiteurs P2Y12 mais quand?...

Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Dmitriy N. Feldman et al. Am J Cardiol. 2010;105(3):323-332.

4033 patients SCA ST-, tropo + Prasugrel en dose de charge versus après coronarographie Critères principal: décès d origine cv, idm, avc, revascularisation urgente, usage d AGP IIb/IIIa)

Total population

Total population

PCI cohort

PCI cohort

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? SCA ST- = plutôt nouveaux inhibiteurs P2Y12 en salle de KT

Conclusion Pas de place à l aspirine seule SCA ST+ inhibiteurs des P2Y12: en amont de la salle de KT Place du prasugrel et du ticagrelor SCA ST- inhibiteurs des P2Y12: en salle de KT Place du prasugrel et du ticagrelor SCA ST- à haut risque?